iLLUMINATE™: IMBRUVICA® + OBINUTUZUMAB 
FOR FRONTLINE CLL/SLL

iLLUMINATE™: ORR with IMBRUVICA® + obinutuzumab for frontline CLL/SLL1,2

Secondary endpoint: Overall response rate IMBRUVICA® + obinutuzumab vs chlorambucil + obinutuzumab (N=229)1

ORR (CR and PR) was assessed by an IRC per iwCLL criteria.2-4

  • Median follow-up was 31 months1
  • 88.5% ORR with IMBRUVICA® + obinutuzumab vs 73% with chlorambucil + obinutuzumab1
    • 19.5% of patients in the IMBRUVICA® + obinutuzumab arm achieved a complete response*
    • 7.8% of patients in the chlorambucil + obinutuzumab arm achieved a complete response
    • 69.0% of patients in the IMBRUVICA® + obinutuzumab arm achieved a partial response
    • 65.5% of patients in the chlorambucil + obinutuzumab arm achieved a partial response

*Includes 1 patient in the IMBRUVICA® + obinutuzumab arm with a complete response with incomplete marrow recovery (CRi).

PR = nPR + PR.

Abbreviations

CLL=chronic lymphocytic leukemia, CR=complete response, CRi= incomplete marrow recovery, IG=ibrutinib + obinutuzumab, IRC=independent review committee, iwCLL=International Workshop on Chronic Lymphocytic Leukemia, GClb=obinutuzumab + chlorambucil, nPR=nodular partial response, ORR=overall response rate, PR=partial response, SLL=small lymphocytic lymphoma.

References

1Moreno C, Griel R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia: primary results from the randomised phase 3 iLLUMINATE study. Lancet Oncol. 2019;20(1):43-56. 2IMBRUVICA® (ibrutinib) Prescribing Information. 3Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute—Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456. 4Hallek M, Cheson BD, Catovsky D, et al. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes (e-Letter). Blood. 2012;119(23):5348.